EIGRQ — Eiger Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview
Brief: Eiger Biopharmaceuticals On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview
Brief: Eiger Biopharmaceuticals Says Debtors Will Continue To Operate Their Businesses As "Debtors-In-Possession" Under Jurisdiction Of Bankruptcy Court
U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
Eiger BioPharmaceuticals plunges on Chapter 11 bankruptcy filing
Brief: Eiger Biopharmaceuticals Files For Voluntary Chapter 11 Protection
Media: Eiger Biopharmaceuticals files for Chapter 11 bankruptcy - Bloomberg News
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview
Brief: Eiger, AnGes Receive Approval for Zokinvy (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Brief: Eiger Biopharmaceuticals, Inc. Announces 1-For-30 Reverse Stock Split
Brief: Moshe Arkin Initially Bought Eiger Biopharmaceuticals Securities Believing Those Were Undervalued & Had Attractive Investment Opportunity
Eiger BioPharmaceuticals Inc expected to post a loss of 32 cents a share - Earnings Preview